160 related articles for article (PubMed ID: 32158279)
1. TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel.
Wardhani BW; Puteri MU; Watanabe Y; Louisa M; Setiabudy R; Kato M
J Exp Pharmacol; 2020; 12():17-26. PubMed ID: 32158279
[TBL] [Abstract][Full Text] [Related]
2. TGF-β-Induced TMEPAI Promotes Epithelial-Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration.
Wardhani BWK; Louisa M; Watanabe Y; Setiabudy R; Kato M
Breast Cancer (Dove Med Press); 2021; 13():529-538. PubMed ID: 34584450
[TBL] [Abstract][Full Text] [Related]
3. TGF-β induced TMEPAI/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer.
Singha PK; Pandeswara S; Geng H; Lan R; Venkatachalam MA; Saikumar P
Genes Cancer; 2014 Sep; 5(9-10):320-36. PubMed ID: 25352949
[TBL] [Abstract][Full Text] [Related]
4. Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer.
Singha PK; Pandeswara S; Geng H; Lan R; Venkatachalam MA; Dobi A; Srivastava S; Saikumar P
Genes Cancer; 2019; 10(5-6):134-149. PubMed ID: 31798766
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer.
Singha PK; Yeh IT; Venkatachalam MA; Saikumar P
Cancer Res; 2010 Aug; 70(15):6377-83. PubMed ID: 20610632
[TBL] [Abstract][Full Text] [Related]
6. PMEPA1/TMEPAI Is a Unique Tumorigenic Activator of AKT Promoting Proteasomal Degradation of PHLPP1 in Triple-Negative Breast Cancer Cells.
Haque MA; Abdelaziz M; Puteri MU; Vo Nguyen TT; Kudo K; Watanabe Y; Kato M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638419
[TBL] [Abstract][Full Text] [Related]
7. PMEPA1/TMEPAI isoforms function via its PY and Smad-interaction motifs for tumorigenic activities of breast cancer cells.
Puteri MU; Watanabe Y; Wardhani BWK; Amalia R; Abdelaziz M; Kato M
Genes Cells; 2020 Jun; 25(6):375-390. PubMed ID: 32181976
[TBL] [Abstract][Full Text] [Related]
8. Cooperative induction of transmembrane prostate androgen induced protein TMEPAI/PMEPA1 by transforming growth factor-β and epidermal growth factor signaling.
Azami S; Vo Nguyen TT; Watanabe Y; Kato M
Biochem Biophys Res Commun; 2015 Jan; 456(2):580-5. PubMed ID: 25482449
[TBL] [Abstract][Full Text] [Related]
9. TMEPAI/PMEPA1 enhances tumorigenic activities in lung cancer cells.
Vo Nguyen TT; Watanabe Y; Shiba A; Noguchi M; Itoh S; Kato M
Cancer Sci; 2014 Mar; 105(3):334-41. PubMed ID: 24438557
[TBL] [Abstract][Full Text] [Related]
10. TMEPAI/PMEPA1 inhibits Wnt signaling by regulating β-catenin stability and nuclear accumulation in triple negative breast cancer cells.
Amalia R; Abdelaziz M; Puteri MU; Hwang J; Anwar F; Watanabe Y; Kato M
Cell Signal; 2019 Jul; 59():24-33. PubMed ID: 30890370
[TBL] [Abstract][Full Text] [Related]
11. C18 ORF1, a novel negative regulator of transforming growth factor-β signaling.
Nakano N; Maeyama K; Sakata N; Itoh F; Akatsu R; Nakata M; Katsu Y; Ikeno S; Togawa Y; Vo Nguyen TT; Watanabe Y; Kato M; Itoh S
J Biol Chem; 2014 May; 289(18):12680-92. PubMed ID: 24627487
[TBL] [Abstract][Full Text] [Related]
12. TMEPAI inhibits TGF-β signaling by promoting lysosome degradation of TGF-β receptor and contributes to lung cancer development.
Bai X; Jing L; Li Y; Li Y; Luo S; Wang S; Zhou J; Liu Z; Diao A
Cell Signal; 2014 Sep; 26(9):2030-9. PubMed ID: 24933703
[TBL] [Abstract][Full Text] [Related]
13. Requirement of TCF7L2 for TGF-beta-dependent transcriptional activation of the TMEPAI gene.
Nakano N; Itoh S; Watanabe Y; Maeyama K; Itoh F; Kato M
J Biol Chem; 2010 Dec; 285(49):38023-33. PubMed ID: 20889500
[TBL] [Abstract][Full Text] [Related]
14. TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling.
Watanabe Y; Itoh S; Goto T; Ohnishi E; Inamitsu M; Itoh F; Satoh K; Wiercinska E; Yang W; Shi L; Tanaka A; Nakano N; Mommaas AM; Shibuya H; Ten Dijke P; Kato M
Mol Cell; 2010 Jan; 37(1):123-34. PubMed ID: 20129061
[TBL] [Abstract][Full Text] [Related]
15. TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways.
Hu Y; He K; Wang D; Yuan X; Liu Y; Ji H; Song J
Carcinogenesis; 2013 Aug; 34(8):1764-72. PubMed ID: 23615405
[TBL] [Abstract][Full Text] [Related]
16. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
17. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
18. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
19. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells.
Chen WC; Lai YA; Lin YC; Ma JW; Huang LF; Yang NS; Ho CT; Kuo SC; Way TD
J Agric Food Chem; 2013 Dec; 61(48):11817-24. PubMed ID: 24236784
[TBL] [Abstract][Full Text] [Related]
20.
Tang L; Chen Y; Chen H; Jiang P; Yan L; Mo D; Tang X; Yan F
Front Oncol; 2020; 10():280. PubMed ID: 32226772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
